載入中
Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.
前收盤價
US$41.17
+US$0.37 · +0.91%
盤中時間採用ET。市場資料可能有所延遲。
Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.
日內區間
目前US$41.17
52週區間
目前US$41.17
盤中時間採用ET。市場資料可能有所延遲。
Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.
日內區間
目前US$41.17
52週區間
目前US$41.17
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 5523.2萬 USD | 9842.7萬 USD | 9012.2萬 USD | 9205.5萬 USD | 1.02億 USD |
| 銷貨成本 | — | 3068.6萬 USD | 3664.4萬 USD | 2163.5萬 USD | 2489.7萬 USD |
| 毛利 | 5523.2萬 USD | 6774.1萬 USD | 5347.8萬 USD | 7042萬 USD | 7701萬 USD |
| 研究與開發 | 1.17億 USD | 1.21億 USD | 1.14億 USD | 2.18億 USD | 4億 USD |
| 銷售、一般及管理費用 | 6867.3萬 USD | 7675.1萬 USD | 7741.7萬 USD | 9233.3萬 USD | 1.23億 USD |
| 營業費用 | 1.86億 USD | 1.73億 USD | 1.91億 USD | 3.11億 USD | 5.23億 USD |
| 利息收入 | 1043.8萬 USD | 1450萬 USD | 1900.9萬 USD | 678.3萬 USD | 273.1萬 USD |
| 利息支出 | 2618.4萬 USD | 2811.2萬 USD | 2533.4萬 USD | 2891.1萬 USD | 4731.3萬 USD |
| 折舊和攤銷 | 102.6萬 USD | 439.1萬 USD | 781.5萬 USD | 1303萬 USD | 1414.6萬 USD |
| 營業利益 | −1.31億 USD | −1.05億 USD | −1.37億 USD | −2.4億 USD | −4.46億 USD |
| 淨利 | −1.64億 USD | −1.19億 USD | −2.76億 USD | −3.68億 USD | −5.24億 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$146
上漲空間 254.63%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2025年6月9日 | 1:15 | — | — |
股票分割 | 2000年8月23日 | 2:1 | — | — |
已生效 2025年6月9日
1:15
已生效 2000年8月23日
2:1
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI7694.03萬0.00%2.3兆 USD0.03%US$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI4032.65萬0.41%98.74億 USD0.35%US$153.77+3.00%
iShares Russell 2000 ETFIWM3703.05萬0.05%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF2804.62萬0.03%954億 USD0.05%US$235+0.80%
Vanguard Russell 2000 ETFVTWO1414.3萬0.08%180億 USD0.06%US$112.66+0.50%
iShares Russell 2000 Growth ETFIWO1164.66萬0.08%139.17億 USD0.24%US$356.78+0.94%
Schwab U.S. Small-Cap ETFSCHA737.15萬0.03%218.24億 USD0.03%US$32.79+0.40%
Vanguard Health Care ETFVHT644.23萬0.03%220億 USD0.09%US$319.01+1.64%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHAVanguard Health Care ETFVHTAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
